Short-course blinatumomab treatment for B-ALL patients with measurable residual disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy of a short course of blinatumomab in patients with B-cell acute lymphoblastic leukemia (B-ALL) who have detectable measurable residual disease (MRD) after achieving a complete response. The treatment involves administering blinatumomab over a 7-day period as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT). The primary goal is to assess the MRD response following this short-course therapy, with evaluations conducted through bone marrow aspiration and next-generation flow cytometry. The study aims to determine the optimal dosing regimen for blinatumomab in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
* MRD detectable in complete response (above the limit of quantification according to FCM)
* Performance status 0-2 on the ECOG scale
* No prior organ damage
* Having a potential related or unrelated donor

Exclusion Criteria:

* Performance status on the ECOG scale \>2
* HCT-CI \>3 points
* Patients who do not wish to participate in clinical study.
* Active central nervous system infiltration (CNS3)
* Active extramedullary disease
* Having previously received blinatumomab
* Absence of related or unrelated donors

Where it's running

• Hospital Universitario Dr. Jose E. Gonzalez
  Monterrey, Nuevo León, Mexico Recruiting

Study contacts

• Study coordinator: Andres Gomez-De Leon, Professor of Hematology
• Email: drgomezdeleon@gmail.com
• Phone: +528116089404

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

• Combining blinatumomab and asciminib for treating a type of leukemia

  This study is testing if combining two drugs, blinatumomab and asciminib, can help people with a specific type of leukemia feel better and improve their chances of recovery.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · The Bronx, New York and 1 other locations · NCT06308588

• Preventing neurotoxicity in leukemia treatment with intrathecal chemotherapy

  This study is testing if giving a specific chemotherapy directly into the spine can help protect the brain from side effects while treating adults with Acute Lymphoblastic Leukemia.

  Recruiting Phase 2 Northside Hospital, Inc. · Atlanta, Georgia · NCT05519579

• Combining blinatumomab, methotrexate, cytarabine, and ponatinib for treating certain types of leukemia

  This study is testing a new combination of four medications to see if it can help people with certain types of leukemia that have come back or didn't respond to previous treatments.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03263572

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies

  This study follows adults with Philadelphia-positive acute lymphoblastic leukemia who are being treated with a combination of BCR-ABL1 inhibitors and other therapies to see how they fare in real-world practice.

  Recruiting at 7 sites Versailles Hospital · Amiens and 22 other locations · NCT07684131

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.